Last updated on May 2020

Hereditary Angioedema (HAE)

Brief description of study

An open-label study to evaluate the long-term safety of daily oral BCX7353 in subjects with Type I and Type II hereditary angioedema.

Detailed Study Description


Subjects who meet the inclusion and exclusion criteria will be enrolled into the study for up to 96 weeks. Enrolled subjects will receive BCX7353 150 mg administered orally once daily (QD).

A total of 8 visits will occur over the course of the subject’s participation in this study. Study visits will occur at Screening, Baseline/Day 1, and at weeks 4, 12, 24, 48, 72, 96. If between scheduled study visits the subject runs out of study medication a visit will be scheduled to dispense more study medication.


Blood tests, electrocardiograms and physical exams.


Clinical Study Identifier: TX244116

Find a site near you

Start Over

Western States Clinical Research, Inc.

4251 Kipling St. Suite 540 Wheat Ridge, Colorado United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.